Research Note - High upfront payments expected through sales partnership for China; “Fast Track†approval obtained from the FDA; Price Target increased to EUR 3.30 (previously: EUR 2.90); BUY rating confirmed
Neovacs is a biotechnology company, which specialises in a technology platform called "Kinoid" for active immunotherapy in the area of autoimmune and inflammatory diseases. On the basis of the company's owntechnology for the introduction of a polyclonal immune response (protected by six patent families until at least 2032). Neovacs focuses its development activities on active immunotherapy with IFNα kinoid, which is being developed for the medical indications SLE (systemic lupus erythematosus) and DM (dermatomyositis).
Neovacs also conducts preclinical trials with IFNα kinoid for type 1-Diabetes, VEGF kinoid for agerelated macular degeneration (AMD) and solid tumors, and IL-4/IL-13 kinoids to treat allergies. The goal of the Kinoid approach is to give patients access to safe treatments which have a lasting positive impact on these chronic diseases.
Die GBC AG mit Sitz in Augsburg ist eines der führenden bankenunabhängigen Investmenthäuser in Deutschland und erfahrener Emissionsexperte für den deutschen Mittelstand.
Die GBC AG kennt als eigentümergeführtes Unternehmen die Bedürfnisse des deutschen Mittelstandes im Finanzierungsbereich und ist ein unabhängiger und verlässlicher Partner bei allen Fragestellungen rund um den Kapitalmarkt.
In der GBC Gruppe bietet die GBC AG Unternehmensanalysen & Research, Kapitalmarkt- & Finanzierungsberatungen sowie Kapitalmarktkonferenzen.
Die GBC Kapital GmbH ergänzt die Leistungen in der Gruppe um das Corporate Finance in den Bereichen Platzierung & Vermittlung von Anleihen und Aktien
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.